Immunovant updates Graves’ Disease trial program

Immunovant, Inc. reported that it issued a press release on September 3, 2025 providing an update on its Graves’ Disease development program.

Accepted by SEC EDGAR 09/03/2025 - 01:09 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Immunovant, Inc. reported that it issued a press release on September 3, 2025 providing an update on its Graves’ Disease development program. The press release is included as an exhibit and is incorporated by reference.

The company also posted an investor presentation on its website covering an update on its Graves’ Disease proof-of-concept study and plans to host a conference call and webcast at 4:30 p.m. E.D.T. to discuss remission data from the trial. The presentation used for this call is filed as a separate exhibit.

8-K Event Classification

3 items: 7.01, 8.01, 9.01

3 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Immunovant (IMVT) report in this 8-K filing?

Immunovant reported that it issued a press release providing an update on its Graves’ Disease development program and attached the release as Exhibit 99.1.

What new materials did Immunovant (IMVT) make available to investors?

The company posted a presentation on the Graves’ Disease proof-of-concept study on the presentations page of its investor relations website and filed it as Exhibit 99.2.

Is Immunovant holding a call related to the Graves’ Disease trial?

Yes. Immunovant plans to host a conference call and webcast to discuss remission data from the Graves’ Disease trial at 4:30 p.m. E.D.T. on September 3, 2025.

Are the Graves’ Disease update materials considered filed with the SEC?

The information under Item 7.01, including Exhibit 99.1, is described as furnished rather than filed and is stated as not subject to Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act.

Where can investors access Immunovant’s Graves’ Disease presentation?

Investors can access the Graves’ Disease proof-of-concept study presentation on the “Presentations” page of Immunovant’s investor relations website and in Exhibit 99.2 to this report.

Who signed this Immunovant (IMVT) 8-K report?

The report was signed on behalf of Immunovant, Inc. by Tiago Girao, the company’s Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001764013FALSE00017640132025-09-032025-09-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 3, 2025

IMMUNOVANT, INC.

(Exact name of Registrant as specified in its Charter)

Delaware						001-38906			83-2771572
(State or other jurisdiction of incorporation or organization)						(Commission File Number)			(IRS Employer Identification No.)
320 West 37th Street
New York,			NY						10018
(Address of principal executive offices)									(Zip Code)

Registrant’s telephone number, including area code: (917) 580-3099

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐        Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

IMVT

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On September 3, 2025, Immunovant, Inc. (the “Company”) issued a press release providing an update on its Graves’ Disease (“GD”) development program. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 8.01. Other Events.

On September 3, 2025, the Company posted a presentation regarding the update on its GD proof-of-concept study on the “Presentations” page of its investor relations website at https://www.immunovant.com/investors and will host a conference call and webcast to discuss the remission data from the GD trial at 4:30 p.m. E.D.T. A copy of the presentation to be used by the Company during the conference call is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The contents of the Company’s website referenced in this Current Report on Form 8-K are not incorporated into this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press release, dated September 3, 2025.
99.2						Presentation, dated September 3, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			IMMUNOVANT, INC.
			By:						/s/ Tiago Girao
									Tiago Girao
									Chief Financial Officer
Date: September 3, 2025